Our investigation reveals that NSCLC cells with EGFR mutations express higher levels of HRS (with no significant change in ALIX) and that the expression level of PD-L1 in circulating sEVs from patients is directly tied to HRS levels in their tumor tissues. Here, EGFR is linked to non-small cell lung carcinoma.